DexCom (NASDAQ:DXCM) Raised to "Strong-Buy" at Wall Street Zen

Key Points

• Wall Street Zen upgraded DexCom from a "buy" to a strong‑buy, while MarketBeat shows a consensus rating of Moderate Buy and a $83.73 average price target.
• DexCom posted a Q1 beat—non‑GAAP EPS $0.56 vs. $0.47 and revenue $1.19B (+15% YoY) with improved margins—but management only reaffirmed FY26 revenue guidance (~$5.2–$5.3B), which led some brokers to trim price targets and shares to pull back.
• Investors view a favorable Medicare National Coverage Determination (NCD) as the biggest 2026 catalyst, and the company cited record new patient starts, product momentum and coverage expansion as drivers of sustained CGM growth.

DexCom (NASDAQ:DXCM - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a report issued on Saturday.

Other research analysts have also recently issued research reports about the stock. Raymond James Financial set a $81.00 price target on shares of DexCom in a report on Friday. Wells Fargo & Company decreased their price target on shares of DexCom from $93.00 to $85.00 and set an "overweight" rating on the stock in a report on Friday, February 13th. TD Cowen decreased their price target on shares of DexCom from $84.00 to $75.00 and set a "buy" rating on the stock in a report on Friday. Mizuho set a $75.00 price target on shares of DexCom in a report on Friday. Finally, Weiss Ratings raised shares of DexCom from a "sell (d+)" rating to a "hold (c-)" rating in a report on Wednesday, March 4th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, DexCom has a consensus rating of "Moderate Buy" and a consensus price target of $83.73.

DexCom Trading Up 3.0%

DexCom stock opened at $61.35 on Friday. The stock has a market cap of $23.67 billion, a P/E ratio of 29.21, a PEG ratio of 1.16 and a beta of 1.40. DexCom has a fifty-two week low of $54.11 and a fifty-two week high of $89.98. The firm's fifty day moving average price is $65.87 and its 200-day moving average price is $66.40. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.59 and a current ratio of 1.88.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.09. The firm had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 34.18%. The business's quarterly revenue was up 15.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.32 earnings per share. Equities research analysts forecast that DexCom will post 2.49 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total value of $107,168.00. Following the transaction, the executive vice president owned 111,204 shares of the company's stock, valued at $7,010,300.16. This represents a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.32% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in DXCM. Reflection Asset Management bought a new position in DexCom in the fourth quarter valued at $25,000. Ascentis Independent Advisors bought a new position in DexCom in the first quarter valued at $25,000. SJS Investment Consulting Inc. increased its stake in DexCom by 4,800.0% in the third quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company's stock valued at $26,000 after acquiring an additional 384 shares during the last quarter. Financial Consulate Inc. bought a new position in DexCom in the third quarter valued at $29,000. Finally, CVA Family Office LLC increased its stake in DexCom by 48.5% in the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company's stock valued at $30,000 after acquiring an additional 147 shares during the last quarter. Institutional investors own 97.75% of the company's stock.

Key DexCom News

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Q1 beat on both EPS and revenue; non‑GAAP EPS of $0.56 topped estimates and revenue rose 15% to $1.19B with margins improving — a clear near‑term earnings beat that supports upside. DexCom Stock Up on Q1 Earnings & Revenues Beat, Margins Rise
• Positive Sentiment: Company reported record new patient starts globally and cites product momentum plus coverage expansion as drivers — supports sustained top‑line growth and market penetration for its CGM franchise. DXCM Q1 deep dive: US growth moderates as product momentum and coverage expansion drive strategy
• Positive Sentiment: Medicare National Coverage Determination (NCD) remains the biggest catalyst for 2026 per RBC — a favorable NCD could materially expand U.S. addressable market and is being watched by investors. DexCom Medicare Coverage NCD Remains Biggest 2026 Catalyst, RBC Says
• Neutral Sentiment: Management reaffirmed FY26 revenue guidance (~$5.2–$5.3B) rather than raising it; that keeps the outlook intact but removes an upside surprise for the full year amid geopolitical caution. Dexcom reaffirms full-year forecast after topping quarterly estimates
• Negative Sentiment: Some brokerages trimmed price targets (TD Cowen cut to $75; BTIG lowered its PT to $80) even as they keep Buy ratings — reduces near‑term analyst upside and may cap gains. Benzinga
• Negative Sentiment: Shares saw an after‑hours pullback in some sessions despite the beat as investors parsed the lack of an upgraded FY revenue outlook and geopolitical risk; watch volume and guidance commentary in the call transcript/slides. Dexcom falls over 5% despite better-than-expected Q1 print, as revenue guidance disappoints

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.